I'm a Mayo specialist in evaluation and management of patients with ulcerative colitis and Crohn's disease. Tweets are mine. Retweet doesn't mean endorsement.
Today is a sad day. Deb and I have worked together for 2 decades. Research and clinical RN extraordinaire. My “secret weapon”! I wish you well in your retirement and I will miss you! (And if u get bored the door is open haha)
@MayoClinicGIHep
Ustekinumab in real-world practice: SUCCESS Consortium just presented by
@amjohnsonMD
#DDW2021
As you might expect, most effective in bio-naive
#Crohns
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results from the SUCCESS Consortium - PubMed
@amjohnsonMD
@PDulaiMD
@AmJGastro
Not all diarrhea is due to
#IBD
even in
#IBD
patients...for example we see a lot of SIBO, bile acid malabsorption, partial short bowel, and occasionally pancreatic insufficiency
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis | Business Wire
US Insurers Out of Step With IBD Treatment Guidelines
There's no scientific reason to require
#IBD
patients to fail 5-ASA or thiopurine/methotrexate monotherapy prior to starting an advanced therapy
Last day in clinic with this guy who I have had privilege to work with over past 4 years
@GuiRamosMD
Not to fear—he will be back in 2 years!
@MayoClinicGIHep
“Glue people”: these are 2 of our secret weapons
@MayoClinicGIHep
Deb in appt office and Susie my admin asst from time immemorial! Deb is retiring after 44 yrs at
@MayoClinic
but she is not allowed to retire!
#ThankfulThursday
Dr Naina Coelho: How to monitor for dysplasia in
#IBD
Strictures especially in UC should be biopsied.
#PSC
IBD needs to be watched especially carefully. Still a role for dye spray chromoendoscopy
#AIBD2023
@NayantaraCoelho
My bro
@Loftus
gave a talk at Alice Mayo Society about his book The Messenger (about Moderna’s development of mRNA SARS-CoV2 vaccine)
@MayoClinic
@HarvardBiz
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial